Truist analyst Les Sulewski raised the firm’s price target on Collegium Pharmaceutical (COLL) to $48 from $45 and keeps a Buy rating on the shares. The company is reaping rewards from solid back-to-school sales and marketing efforts, which pushed Jornay PM to record revenue, the analyst tells investors in a research note. The outperformance, along with another beat for the pain portfolio, prompted the management to once again raise 2025 guidance across the board, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceuticals Reports Record Growth and Optimistic Outlook
- Collegium Pharmaceutical price target raised to $46 from $44 at H.C. Wainwright
- Collegium Pharmaceutical Reports Record Q3 2025 Results
- Collegium Pharmaceutical Reports Strong Q3 2025 Financial Results
- Collegium raises FY25 revenue view to $775M-$785M from $745M-$760M